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Clinical PerspectiveWhat Is New?In a large, real‐life cohort study in patients with type 2 diabetes mellitus and hypertension in Italy, the presence of apparent treatment resistant hypertension entails a significantly greater risk of developing chronic kidney disease and/or a clinically relevant reduction in estimated glomerular filtration rate over a 4‐year follow‐up.The achievement and maintenance of recommended blood pressure values (ie, 75% of visits with blood pressure \<140/90 mm Hg) are associated with a worse renal outcome in apparent treatment resistant hypertension patients.The relationship between achieved blood pressure and renal function seems to be J‐shaped, at least at very low levels, with optimal systolic blood pressure values between 120 and 140 mm Hg.What Are the Clinical Implications?There is a need for early identification and management of patients to prevent the development of apparent treatment resistant hypertension and associated increase in renal morbidity.Reduction of antihypertensive treatment should be considered in a small, but relevant, proportion of patients in order to improve renal outcome.

Introduction {#jah32537-sec-0008}
============

Resistant hypertension (RH), that is, blood pressure (BP) above target levels despite optimal combination of at least 3 different drugs, including a diuretic,[1](#jah32537-bib-0001){ref-type="ref"}, [2](#jah32537-bib-0002){ref-type="ref"}, [3](#jah32537-bib-0003){ref-type="ref"} is highly prevalent in patients at high cardiovascular risk, such as those with diabetes mellitus and chronic kidney disease (CKD).[4](#jah32537-bib-0004){ref-type="ref"}, [5](#jah32537-bib-0005){ref-type="ref"}, [6](#jah32537-bib-0006){ref-type="ref"} The real prevalence of RH has been reported to vary considerably, from 10% to 40%,[3](#jah32537-bib-0003){ref-type="ref"}, [7](#jah32537-bib-0007){ref-type="ref"} because of several confounding factors, and the term apparent treatment resistant hypertension (aTRH) should be preferred when adherence to medications or out‐of‐office BP are unknown.[8](#jah32537-bib-0008){ref-type="ref"}

ATRH has been associated with worse cardiovascular morbidity and mortality[9](#jah32537-bib-0009){ref-type="ref"}, [10](#jah32537-bib-0010){ref-type="ref"} and faster progression of renal disease in CKD patients,[6](#jah32537-bib-0006){ref-type="ref"}, [11](#jah32537-bib-0011){ref-type="ref"} underscoring the need for early identification and systematic evaluation and management of at‐risk patients. In a recent, large, 5‐year retrospective study among over 470 000 individuals from the Kaiser Permanente Southern California registry, those with RH had a greater risk for end‐stage renal disease (ESRD), ischemic heart event, congestive heart failure, cerebrovascular accident, and all‐cause mortality. The risk of ESRD and cerebrovascular accident were 25% and 23% greater, respectively, in RH compared with non‐RH, supporting the linkage between severity of BP and both outcomes.[12](#jah32537-bib-0012){ref-type="ref"}

Furthermore, and somewhat unexpectedly, in patients with aTRH, the achievement of recommended BP control does not seem to entail any cardiovascular benefit[9](#jah32537-bib-0009){ref-type="ref"}, [13](#jah32537-bib-0013){ref-type="ref"}, [14](#jah32537-bib-0014){ref-type="ref"} and, possibly, is associated with a greater renal risk as compared with patients with uncontrolled aTRH.[3](#jah32537-bib-0003){ref-type="ref"} In a recent retrospective study on a large cohort of treated hypertensive patients in the United States, low treated BP (systolic BP \[SBP\] \<120 and/or diastolic BP \[DBP\] \<70 mm Hg) was associated with more cardiovascular diseases than less‐stringent BP control irrespective of aTRH.[15](#jah32537-bib-0015){ref-type="ref"}

These data raise the possibility that a J‐curve effect for cardiovascular and renal disease is present, and perhaps even more evident, in the subgroup of patients with aTRH who are likely to be more adherent to treatment, but also show a worse risk profile.

Specific data on long‐term renal outcome in aTRH are scanty, especially in real‐life clinical conditions and with regard to de novo development of organ damage in high‐risk subgroups. To get more insights on the relationship between the presence of aTRH, achievement and maintenance of recommended BP values, and renal outcome, we looked at the incidence of low estimated glomerular filtration rate (eGFR) over a 4‐year follow‐up in a large, real‐life cohort of patients with hypertension and type 2 diabetes mellitus (T2D) in Italy.

Methods {#jah32537-sec-0009}
=======

Study Participants {#jah32537-sec-0010}
------------------

As already reported,[6](#jah32537-bib-0006){ref-type="ref"}, [7](#jah32537-bib-0007){ref-type="ref"}, [8](#jah32537-bib-0008){ref-type="ref"}, [9](#jah32537-bib-0009){ref-type="ref"}, [10](#jah32537-bib-0010){ref-type="ref"}, [11](#jah32537-bib-0011){ref-type="ref"}, [12](#jah32537-bib-0012){ref-type="ref"}, [13](#jah32537-bib-0013){ref-type="ref"}, [14](#jah32537-bib-0014){ref-type="ref"}, [15](#jah32537-bib-0015){ref-type="ref"}, [16](#jah32537-bib-0016){ref-type="ref"}, [17](#jah32537-bib-0017){ref-type="ref"}, [18](#jah32537-bib-0018){ref-type="ref"} in Italy, diabetes mellitus care is mostly provided by a public network of approximately 700 diabetes mellitus clinics in which a team of specialists provides diagnostic confirmation, prevention, and treatment for diabetes mellitus and its complications through close patients follow‐up and regular checkups.[16](#jah32537-bib-0016){ref-type="ref"}, [17](#jah32537-bib-0017){ref-type="ref"}, [18](#jah32537-bib-0018){ref-type="ref"} In the present study, we analyze a large cohort of patients with T2D followed up at 134 diabetes mellitus centers in Italy among those participating in the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi) initiative. The analysis was performed using the data set of electronic medical records collected between January 1, 2004 and June 30, 2011. For the purpose of the analysis, we considered only patients at least 18 years old and with a follow‐up evaluation within 6 months complete for data about BP values, eGFR, albuminuria (Alb), and information on treatment.

Of 64 893 patients identified, after exclusion of 34 970 patients without a confirmed eGFR value above 60 mL/min, or medication information, or a diagnosis of hypertension (SBP \<140 mm Hg and DBP \<90 mm Hg and not taking antihypertensive medications at baseline), a total of 29 923 patients from 132 clinics constitute the study population (Figure [1](#jah32537-fig-0001){ref-type="fig"}). The centers involved in the study were homogeneously distributed throughout the country.

![Flow diagram for selection of study patients. eGFR indicates estimated glomerular filtration rate.](JAH3-6-e006745-g001){#jah32537-fig-0001}

Study Design {#jah32537-sec-0011}
------------

The analysis of the database is an attempt by the Italian Associazione Medici Diabetologi initiative to identify a set of indicators that can be used in the context of continuous quality improvement. Participating centers adopted the same software systems for everyday management of outpatients, whereas a specially developed software package allowed us to extract the information we intended to analyze from all the clinical databases (Associazione Medici Diabetologi Data File). Moreover, data from all participating centers were collected and centrally analyzed anonymously. All patients gave their informed consent, and internal approval was obtained by the Associazione Medici Diabetologi Annals scientific committee.[16](#jah32537-bib-0016){ref-type="ref"}, [17](#jah32537-bib-0017){ref-type="ref"}, [18](#jah32537-bib-0018){ref-type="ref"} The current initiative includes measuring and monitoring glycated hemoglobin (HbA1c), BP, low‐density lipoprotein cholesterol, total and high‐density lipoprotein cholesterol, and triglycerides. The use of specific classes of drugs was also evaluated. Because normal ranges for HbA1c varied among centers, the percentage change with respect to the upper normal value (measured value/upper normal limit) was estimated and multiplied by 6.0 to allow comparisons among the centers. Kidney function was assessed by serum creatinine and urinary albumin excretion measurements. GFR was estimated for each patient using a standardized serum creatinine assay and the Chronic Kidney Disease Epidemiology Collaboration formula.[19](#jah32537-bib-0019){ref-type="ref"} Increased urinary albumin excretion was diagnosed and defined as Alb if urinary albumin concentration was more than 30 mg/L, urinary albumin excretion rate was more than 20 mg/min, or urinary albumin‐to‐creatinine ratio was more than 2.5 mg/mmol in men and more than 3.5 mg/mmol in women. At each participating center, all patients underwent physical examination and BP measurements according to a standardized protocol. BP was measured with the patient in the sitting position after a 5‐minute rest, with a mercury sphygmomanometer. SBP and DBP were read to the nearest 2 mm Hg. Disappearance of Korotkoff sounds (phase V) was the criterion for DBP. Three measurements were taken at 2‐minute intervals, and the average value was used to define clinical SBP and DBP.

The main analysis was aimed at evaluating the association between aTRH, BP control (BPC), and renal outcome during the study. For each outcome, visits after the event occurrence were excluded from the BPC evaluation. The outcomes were: (1) eGFR less than 60 mL/min per 1.73 m^2^; (2) a reduction ≥30% from baseline; and (3) a combination of either 1 of the above end points.

Definition of ATRH and BPC {#jah32537-sec-0012}
--------------------------

We defined ATRH as SBP or DBP≥the BP goal while taking ≥3 antihypertensive medications, including a diuretic, or taking ≥4 antihypertensive medications, including a diuretic, regardless of BP values at baseline visit. The BP goal of \<140/90 mm Hg used for this analysis is consistent with the recommended BP goal for patients with diabetes mellitus in recent guidelines.[20](#jah32537-bib-0020){ref-type="ref"}, [21](#jah32537-bib-0021){ref-type="ref"}

Time‐updated BPC was defined as \>75% of visits with SBP and DBP \<140/90 mm Hg, whereas in secondary analyses time‐updated mean SBP was examined as the average of all available SBP values before the occurrence of the end point, if any.

Statistical Analysis {#jah32537-sec-0013}
--------------------

Data are given as mean values± SD; categorical variables are described as frequencies and percentages. Data were analyzed by mixed models with diabetes mellitus clinics fitted as random effect considering patients as clusters of observations to take into account possible differences across centers. Continuous variables were analyzed with a linear mixed regression model and categorical variables by using a mixed logistic regression model. Odds ratios (ORs) for each renal outcome were reported with their 95% confidence interval (95% CI). A multivariate model was fitted with a complete‐case analysis performed, including patients for which all data were observed. Assuming linearity of GFR reduction over time, its slope was taken as a measure of disease progression rate. For each patient, we calculated the regression coefficient (slope) of linear regression between eGFR value and the exact time in years from the first evaluation, including all measurements from baseline to the 4‐year visit. The analyses were carried out using STATA software (version 14; StataCorp LP, College Station, TX). *P* values of \<0.05 were considered statistically significant.

Results {#jah32537-sec-0014}
=======

Among the 64 893 patients evaluated annually over 4 years for arterial BP and eGFR and with a baseline classification for Alb, a confirmed past eGFR value above 60 mL/min, complete information about medications, and a diagnosis of hypertension, 29 923 patients have been selected for the present analyses (Figure [1](#jah32537-fig-0001){ref-type="fig"}).

Overall, the mean age was 65±9 years, 57% of patients were men, and the mean duration of diabetes mellitus was 11±8 years. The glycometabolic status of participants was fairly good, being the mean values of HbA1c and low‐density lipoprotein cholesterol of 7.3±1.3% and 110±33 mg/dL, respectively. The average BP was 143±17/81±9 mm Hg, with 73% of patients showing either SBP or DBP values above 140/85 mm Hg at the baseline visit. Seventy‐seven percent of patients were receiving antihypertensive treatment (with a mean of 1.6±1.3 drugs per patient), and 65% were taking an angiotensin‐converting enzyme inhibitor or an angiotensin II receptor antagonist. eGFR was 86±13 mL/min per 1.73 m^2^, and 19.6% of patients had increased albuminuria (Table [1](#jah32537-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline Characteristics of Study Patients Stratified by ATRH

                                                   All              No aTRH          aTRH            *P* Value
  ------------------------------------------------ ---------------- ---------------- --------------- -----------
  Male sex                                         16 969 (56.7%)   14 432 (57.9%)   2537 (50.9%)    \<0.001
  Age, y                                           65±9             64±9             67±8            \<0.001
  Known duration of diabetes mellitus, y           11±8             10±8             11±8            \<0.001
  BMI, kg/m^2^                                     30±5             29±5             31±5            \<0.001
  Serum creatinine, μmol/L                         74±15            73±15            74±15           0.005
  eGFR, mL/min per 1.73 m^2^                       86±13            86±13            83±13           \<0.001
  Albuminuria                                      5874 (19.6%)     4772 (19.1%)     1102 (22.1%)    \<0.001
  Microalbuminuria                                 5121 (17.1%)     4172 (16.7%)     949 (19.0%)     \<0.001
  Macroalbuminuria                                 753 (2.5%)       600 (2.4%)       153 (3.1%)      0.001
  Serum uric acid, μmol/L                          315±101          311±102          337±94          \<0.001
  SUA in the top sex‐specific quintile             2878 (19.3%)     2112 (17.1%)     766 (30.0%)     \<0.001
  HbA1c, %                                         7.3±1.3          7.2±1.3          7.3±1.3         0.049
  HbA1c, mmol/mol                                  55.7±14.0        55.7±14.0        56.1±14.1       0.049
  HbA1c ≥7% (≥53 mmol/mol)                         15 987 (53.8%)   13 244 (53.5%)   2743 (55.5%)    0.026
  Total cholesterol, mmol/L                        4.83±0.96        4.85±0.97        4.71±0.93       \<0.001
  Triglycerides, mmol/L                            1.55±0.98        1.54±1.00        1.58±0.89       0.002
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          8780 (31.2%)     7181 (30.6%)     1599 (34.2%)    \<0.001
  HDL, mmol/L                                      1.32±0.38        1.33±0.38        1.29±0.37       \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   8657 (31.2%)     7009 (30.3%)     1648 (36.0%)    \<0.001
  LDL, mmol/L                                      2.84±0.85        2.86±0.85        2.73±0.82       \<0.001
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    16 483 (59.7%)   14 009 (60.8%)   2474 (54.4%)    \<0.001
  Systolic BP, mm Hg                               143±17           142±17           148±18          \<0.001
  Diastolic BP, mm Hg                              81±9             81±9             82±10           \<0.001
  BP ≥140/85 mm Hg                                 21 711 (72.6%)   17 491 (70.1%)   4220 (84.6%)    \<0.001
  Nonproliferative retinopathy                     3955 (13.2%)     3301 (13.2%)     654 (13.1%)     0.906
  Proliferative retinopathy                        1169 (3.9%)      934 (3.7%)       235 (4.7%)      0.002
  Lipid‐lowering treatment                         14 579 (48.7%)   11 716 (47.0%)   2863 (57.4%)    \<0.001
  Treatment with statins                           13 456 (45.0%)   10 773 (43.2%)   2683 (53.8%)    \<0.001
  Treatment with fibrates                          656 (2.2%)       559 (2.2%)       97 (1.9%)       0.123
  No. of antihypertensive drugs                    1.6±1.3          1.2±1.0          3.6±0.8         ...
  Antihypertensive treatment                       23 106 (77.2%)   18 117 (72.7%)   4989 (100.0%)   ...
  Treatment with ACE‐Is/ARBs                       19 512 (65.2%)   14 767 (59.2%)   4745 (95.1%)    ...
  Aspirin                                          9296 (31.1%)     7354 (29.5%)     1942 (38.9%)    \<0.001
  Antidiabetic therapy                                                                               
  Diet                                             2177 (7.3%)      1853 (7.4%)      324 (6.5%)      0.018
  Oral antidiabetic drugs                          20 137 (67.3%)   16 864 (67.6%)   3273 (65.6%)    0.008
  Oral antidiabetic drugs and insulin              4559 (15.2%)     3672 (14.7%)     887 (17.8%)     \<0.001
  Insulin                                          3050 (10.2%)     2545 (10.2%)     505 (10.1%)     0.738

Mean±SD or absolute frequency (percentage). Patients\' baseline missing data: known duration of diabetes mellitus in 937 (3.1%), BMI in 1600 (5.3%), serum uric acid in 15 003 (50.1%), HbA1c in 231 (0.8%), total cholesterol in 2078 (6.9%), triglycerides in 1805 (6%), HDL in 2178 (7.3%), LDL in 2319 (7.7%), and smoking status in 13 650 (45.6%). ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; SUA, serum uric acid.

The prevalence of aTRH was 16.6% (n=4989). The baseline characteristics of patients with and without aTRH are also detailed in Table [1](#jah32537-tbl-0001){ref-type="table-wrap"}. Those with aTRH were more likely to be woman, older, with a longer duration of diabetes mellitus, and to have higher body mass index as compared with those without aTRH. On average, patients with aTRH had higher BP and HbA1c values and lower total, low‐density, and high‐density lipoprotein cholesterol levels than those without aTRH. Moreover, the former group had lower eGFR, higher serum uric acid levels, and were more likely to have Alb and proliferative retinopathy. As expected, patients with aTRH were more likely to be prescribed antihypertensive treatment (especially with diuretics and renin‐angiotensin‐aldosterone system--inhibiting agents) and lipid‐lowering treatment.

Over the 4‐year study follow‐up, 19% (n=5707) developed low eGFR, 12% (n=3551) an eGFR reduction ≥30% from baseline, and 21% (n=6422) a combination of either 1 of the above renal end points. Patients with aTRH showed a higher cumulative incidence for renal end point and increased risk of developing both renal outcome (adjusted OR, 1.31; CI, 1.19--1.44; *P*\<0.001; OR, 1.43, CI, 1.28--1.58; *P*\<0.001; and OR, 1.30, CI, 1.19--1.42; *P*\<0.001, respectively), as compared with those without aTRH (Figure [2](#jah32537-fig-0002){ref-type="fig"}).

![Cumulative incidence of renal outcomes in patients with and without aTRH and T2D. ATRH indicates apparent treatment resistant hypertension; CI, confidence interval; eGFR, estimated glomerular filtration rate; T2D, type 2 diabetes mellitus. \**P*\<0.001 vs No‐aTRH. Adjusted odds ratios for eGFR \<60 mL/min per 1.73 m^2^, 1.31 (CI 1.19--1.44; *P*\<0.001), for eGFR reduction \>30% from baseline, 1.43 (CI 1.28--1.58; *P*\<0.001), for eGFR \<60 or reduction \>30% from baseline, 1.30 (CI 1.19--1.42; *P*\<0.001).](JAH3-6-e006745-g002){#jah32537-fig-0002}

Baseline clinical features of patients grouped on the basis of achieved renal outcome within the study period are reported in Table [2](#jah32537-tbl-0002){ref-type="table-wrap"}. On average, patients who went on to develop low eGFR, an eGFR reduction ≥30% from baseline, or either 1 of the renal end points showed a worse clinical and metabolic profile. They were older, with a longer duration of diabetes mellitus, were more likely to be woman, and to show albuminuria and proliferative retinopathy. Moreover, they had lower GFR values and higher serum uric acid, HbA1c levels, and BP values, with a greater prevalence of aTRH and similar BPC despite a greater prevalence of antihypertensive and insulin treatment.

###### 

Baseline Characteristics of Study Patients on the Basis of Renal Outcome Within 4‐Year

                                                   eGFR \<60 mL/min per 1.73 m^2^   eGFR Reduction \>30%   eGFR \<60 or Reduction \>30%                                                                             
  ------------------------------------------------ -------------------------------- ---------------------- ------------------------------ ---------------- -------------- --------- ---------------- -------------- ---------
  Male sex                                         14 071 (58.1%)                   2898 (50.8%)           \<0.001                        15 247 (57.8%)   1722 (48.5%)   \<0.001   13 743 (58.5%)   3226 (50.2%)   \<0.001
  Age, y                                           64±9                             69±8                   \<0.001                        64±9             67±9           \<0.001   64±9             68±8           \<0.001
  Known duration of diabetes mellitus, y           10±8                             12±9                   \<0.001                        10±8             11±9           \<0.001   10±8             12±9           \<0.001
  BMI, kg/m^2^                                     30±5                             30±5                   0.132                          30±5             30±5           \<0.001   30±5             30±5           0.002
  Serum creatinine, μmol/L                         72±14                            81±14                  \<0.001                        74±15            72±15          \<0.001   72±14            79±15          \<0.001
  eGFR, mL/min per 1.73 m^2^                       88±12                            75±11                  \<0.001                        86±13            85±13          \<0.001   88±12            77±13          \<0.001
  Albuminuria                                      4350 (18.0%)                     1524 (26.7%)           \<0.001                        4846 (18.4%)     1028 (28.9%)   \<0.001   4173 (17.8%)     1701 (26.5%)   \<0.001
  Microalbuminuria                                 3899 (16.1%)                     1222 (21.4%)           \<0.001                        4310 (16.3%)     811 (22.8%)    \<0.001   3746 (15.9%)     1375 (21.4%)   \<0.001
  Macroalbuminuria                                 451 (1.9%)                       302 (5.3%)             \<0.001                        536 (2.0%)       217 (6.1%)     \<0.001   427 (1.8%)       326 (5.1%)     \<0.001
  Serum uric acid, μmol/L                          311±98                           335±113                \<0.001                        314±97           327±130        \<0.001   311±98           331±110        \<0.001
  SUA in the top sex‐specific quintile             2121 (17.5%)                     757 (27.0%)            \<0.001                        2473 (18.7%)     405 (23.8%)    \<0.001   2068 (17.5%)     810 (26.0%)    \<0.001
  HbA1c, %                                         7.2±1.3                          7.3±1.3                \<0.001                        7.2±1.3          7.4±1.4        \<0.001   7.2±1.3          7.4±1.3        \<0.001
  HbA1c, mmol/mol                                  56±14                            57±14                  \<0.001                        56±14            58±15          \<0.001   55±14            57±14          \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         12 725 (52.9%)                   3262 (57.7%)           \<0.001                        13 920 (53.2%)   2067 (58.8%)   \<0.001   12 328 (52.8%)   3659 (57.6%)   \<0.001
  Total cholesterol, mmol/L                        4.84±0.96                        4.78±0.96              \<0.001                        4.84±0.96        4.75±0.97      \<0.001   4.84±0.96        4.78±0.97      \<0.001
  Triglycerides, mmol/L                            1.53±0.98                        1.62±0.98              \<0.001                        1.53±0.97        1.65±1.07      \<0.001   1.53±0.98        1.63±1.00      \<0.001
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          6933 (30.5%)                     1847 (34.4%)           \<0.001                        7612 (30.7%)     1168 (34.9%)   \<0.001   6687 (30.3%)     2093 (34.7%)   \<0.001
  HDL, mmol/L                                      1.32±0.37                        1.32±0.39              0.290                          1.32±0.37        1.31±0.39      0.396     1.32±0.37        1.32±0.39      0.198
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   6876 (30.6%)                     1781 (33.9%)           \<0.001                        7502 (30.7%)     1155 (35.3%)   \<0.001   6641 (30.4%)     2016 (34.1%)   \<0.001
  LDL, mmol/L                                      2.86±0.85                        2.77±0.85              \<0.001                        2.85±0.85        2.74±0.85      \<0.001   2.86±0.85        2.77±0.85      \<0.001
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    13 569 (60.7%)                   2914 (55.6%)           \<0.001                        14 724 (60.5%)   1759 (54.1%)   \<0.001   13 205 (60.8%)   3278 (55.8%)   \<0.001
  Systolic BP, mm Hg                               143±17                           145±18                 \<0.001                        143±17           145±18         \<0.001   143±17           144±18         \<0.001
  Diastolic BP, mm Hg                              81±9                             80±9                   \<0.001                        81±9             81±10          0.018     81±9             80±9           \<0.001
  BP ≥140/85 mm Hg                                 17 599 (72.7%)                   4112 (72.1%)           0.221                          19 113 (72.5%)   2598 (73.2%)   0.345     17 073 (72.6%)   4638 (72.2%)   0.365
  Nonproliferative retinopathy                     3056 (12.6%)                     899 (15.8%)            \<0.001                        3403 (12.9%)     552 (15.5%)    \<0.001   2958 (12.6%)     997 (15.5%)    \<0.001
  Proliferative retinopathy                        861 (3.6%)                       308 (5.4%)             \<0.001                        972 (3.7%)       197 (5.5%)     \<0.001   820 (3.5%)       349 (5.4%)     \<0.001
  Lipid‐lowering treatment                         11 610 (47.9%)                   2969 (52.0%)           \<0.001                        12 806 (48.6%)   1773 (49.9%)   0.218     11 270 (48.0%)   3309 (51.5%)   \<0.001
  Treatment with statins                           10 736 (44.3%)                   2720 (47.7%)           \<0.001                        11 842 (44.9%)   1614 (45.5%)   0.769     10 436 (44.4%)   3020 (47.0%)   \<0.001
  Treatment with fibrates                          512 (2.1%)                       144 (2.5%)             0.090                          564 (2.1%)       92 (2.6%)      0.117     489 (2.1%)       167 (2.6%)     0.021
  Antihypertensive treatment                       18 276 (75.5%)                   4830 (84.6%)           \<0.001                        20 170 (76.5%)   2936 (82.7%)   \<0.001   17 728 (75.4%)   5378 (83.7%)   \<0.001
  Treatment with ACE‐Is/ARBs                       15 408 (63.6%)                   4104 (71.9%)           \<0.001                        17 015 (64.5%)   2497 (70.3%)   \<0.001   14 936 (63.6%)   4576 (71.3%)   \<0.001
  Aspirin                                          7243 (29.9%)                     2053 (36.0%)           \<0.001                        8132 (30.8%)     1164 (32.8%)   \<0.001   7050 (30.0%)     2246 (35.0%)   \<0.001
  Antidiabetic therapy                                                                                                                                                                                              
  Diet                                             1919 (7.9%)                      258 (4.5%)             \<0.001                        2043 (7.7%)      134 (3.8%)     \<0.001   1890 (8.0%)      287 (4.5%)     \<0.001
  Oral antidiabetic drugs                          16 581 (68.5%)                   3556 (62.3%)           \<0.001                        17 898 (67.9%)   2239 (63.1%)   \<0.001   16 105 (68.5%)   4032 (62.8%)   \<0.001
  Oral antidiabetic drugs and insulin              3424 (14.1%)                     1135 (19.9%)           \<0.001                        3819 (14.5%)     740 (20.8%)    \<0.001   3284 (14.0%)     1275 (19.9%)   \<0.001
  Insulin                                          2292 (9.5%)                      758 (13.3%)            \<0.001                        2612 (9.9%)      438 (12.3%)    0.001     2222 (9.5%)      828 (12.9%)    \<0.001
  Apparent treatment resistant hypertension        3631 (15.0%)                     1358 (23.8%)           \<0.001                        4143 (15.7%)     846 (23.8%)    \<0.001   3507 (14.9%)     1482 (23.1%)   \<0.001
  BPC[a](#jah32537-note-0005){ref-type="fn"}       3859 (15.9%)                     853 (14.9%)            0.117                          4200 (15.9%)     553 (15.6%)    0.540     3751 (16.0%)     972 (15.1%)    0.168

Mean±SD or absolute frequency (percentage). ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; SUA, serum uric acid.

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded.

BP changes during follow‐up are shown in Figure [3](#jah32537-fig-0003){ref-type="fig"}.

![Blood pressure changes during follow‐up. ATRH indicates apparent treatment resistant hypertension; BP, blood pressure; blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg.](JAH3-6-e006745-g003){#jah32537-fig-0003}

Additional analyses explored the relationship between different hypertension categories on the basis of aTRH and time‐updated BPC and renal outcomes. Individuals without BPC were more likely to be woman, were older, and with a longer duration of diabetes mellitus and higher body mass index as compared with those with persistent BPC independently of aTRH status (Table [3](#jah32537-tbl-0003){ref-type="table-wrap"}). On average, patients without BPC had higher BP values and HbA1c and total, low‐density, and high‐density lipoprotein cholesterol levels than those with good BPC. Despite similar eGFR values, patients without persistent BPC were more likely to show serum uric acid in the top sex‐specific quintile, Alb, and proliferative retinopathy. As expected, patients without BPC were less likely to be prescribed antihypertensive treatment (number of drugs 1.2±1.0 versus 1.6±0.9 for no aTRH; *P*\<0.01; and 3.6±0.8 versus 4.0±0.7 for aTRH; *P*\<0.01) and lipid‐lowering treatment as compared with those with BPC.

###### 

Baseline Characteristics of Study Patients and Renal Outcomes During the 4‐Year Follow‐up Stratified by ATRH and BPC

                                                     No ATRH        No ATRH          ATRH           ATRH            *P* Value
  -------------------------------------------------- -------------- ---------------- -------------- --------------- -----------
  Male sex                                           2461 (58.6%)   11 971 (57.7%)   280 (54.5%)    2257 (50.4%)    \<0.001
  Age, y                                             63±9           65±9             65±9           67±8            \<0.001
  Known duration of diabetes mellitus, y             10±8           11±8             10±9           11±8            \<0.001
  BMI, kg/m^2^                                       29±5           29±5             31±6           32±5            \<0.001
  Serum creatinine, μmol/L                           75±15          73±15            75±15          74±15           \<0.001
  eGFR, mL/min per 1.73 m^2^                         86±14          86±13            83±13          83±13           \<0.001
  Albuminuria                                        694 (16.5%)    4078 (19.7%)     91 (17.7%)     1011 (22.6%)    \<0.001
  Microalbuminuria                                   616 (14.7%)    3556 (17.1%)     81 (15.8%)     868 (19.4%)     \<0.001
  Macroalbuminuria                                   78 (1.9%)      522 (2.5%)       10 (1.9%)      143 (3.2%)      \<0.001
  Serum uric acid, μmol/L                            314±78         310±107          339±88         336±95          \<0.001
  Serum uric acid in the top sex‐specific quintile   491 (20.2%)    1847 (18.6%)     114 (36.4%)    720 (32.1%)     \<0.001
  HbA1c, %                                           7.1±1.2        7.3±1.3          7.2±1.3        7.3±1.3         \<0.001
  HbA1c, mmol/mol                                    54±13          56±14            55±14          56±14           \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                           2019 (48.5%)   11 225 (54.5%)   256 (50.6%)    2487 (56.1%)    \<0.001
  Total cholesterol, mmol/L                          4.68±0.95      4.89±0.97        4.48±0.83      4.74±0.94       \<0.001
  Triglycerides, mmol/L                              1.51±0.94      1.55±1.01        1.61±0.89      1.58±0.89       0.010
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)            1172 (29.5%)   6009 (30.9%)     173 (36.2%)    1426 (33.9%)    \<0.001
  HDL, mmol/L                                        1.28±0.39      1.34±0.37        1.23±0.37      1.30±0.37       \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)     1373 (34.8%)   5636 (29.3%)     199 (42.2%)    1449 (35.3%)    \<0.001
  LDL, mmol/L                                        2.75±0.84      2.88±0.85        2.56±0.76      2.75±0.83       \<0.001
  LDL ≥100 mg/dL (≥2.59 mmol/L)                      2155 (55.1%)   11 854 (61.9%)   219 (47.2%)    2255 (55.2%)    \<0.001
  Systolic BP, mm Hg                                 126±12         145±16           129±14         150±17          \<0.001
  Diastolic BP, mm Hg                                76±8           82±9             77±9           83±9            \<0.001
  BP ≥140/85 mm Hg                                   893 (21.3%)    16 598 (80.0%)   165 (32.1%)    4055 (90.6%)    \<0.001
  Nonproliferative retinopathy                       500 (11.9%)    2801 (13.5%)     59 (11.5%)     595 (13.3%)     0.008
  Proliferative retinopathy                          139 (3.3%)     795 (3.8%)       24 (4.7%)      211 (4.7%)      0.001
  Smokers                                            453 (18.6%)    1853 (16.7%)     44 (14.9%)     285 (11.7%)     \<0.001
  Lipid‐lowering treatment                           2427 (57.8%)   9289 (44.8%)     332 (64.6%)    2531 (56.6%)    \<0.001
  Treatment with statins                             2246 (53.5%)   8527 (41.1%)     304 (59.1%)    2379 (53.2%)    \<0.001
  Treatment with fibrates                            104 (2.5%)     455 (2.2%)       7 (1.4%)       90 (2.0%)       0.205
  Antihypertensive treatment                         3869 (92.2%)   14 248 (68.7%)   514 (100.0%)   4475 (100.0%)   \<0.001
  Treatment with ACE‐Is/ARBs                         3069 (73.1%)   11 698 (56.4%)   494 (96.1%)    4251 (95.0%)    \<0.001
  Aspirin                                            1539 (36.7%)   5815 (28.0%)     197 (38.3%)    1745 (39.0%)    \<0.001
  Antidiabetic therapy                                                                                              
  Diet                                               361 (8.6%)     1492 (7.2%)      36 (7.0%)      288 (6.4%)      0.024
  Oral antidiabetic drugs                            2807 (66.9%)   14 057 (67.8%)   328 (63.8%)    2945 (65.8%)    0.007
  Oral antidiabetic drugs and insulin                555 (13.2%)    3117 (15.0%)     80 (15.6%)     807 (18.0%)     \<0.001
  Insulin                                            475 (11.3%)    2070 (10.0%)     70 (13.6%)     435 (9.7%)      0.007

The *P* values refer to the overall significance of logistic mixed regression model for categorical data or linear for continuous variables with blood pressure group as dependent variable. Mean±SD or absolute frequency (percentage). ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; aTRH, apparent resistant hypertension; BMI, body mass index; BP, blood pressure; BPC, blood pressure control; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

When we performed a multivariate analysis, age, body mass index, low eGFR, presence of Alb and of proliferative retinopathy, worse lipid profile (suggestive of the insulin resistance state), and the prescription of insulin and antihypertensive treatment were significantly and independently associated with a greater risk of incident eGFR below 60 mL/min and renal function worsening, as indicated in Table [4](#jah32537-tbl-0004){ref-type="table-wrap"}. At variance, we found no independent relationship between known duration of diabetes mellitus, baseline HbA1c, and several treatments for cardiovascular protection, such as lipid‐lowering treatment, renin‐angiotensin‐aldosterone system inhibition, or aspirin, and anyone of the renal end points taken into consideration in this generally well‐treated study cohort (Table [4](#jah32537-tbl-0004){ref-type="table-wrap"}).

###### 

Multivariate Analysis for the Occurrence of 4‐Year Renal Outcome

                                                   eGFR \<60 mL/min per 1.73 m^2^   eGFR Reduction ≥30%   eGFR \<60 or Reduction ≥30%                                 
  ------------------------------------------------ -------------------------------- --------------------- ----------------------------- --------- ------------------- ---------
  Male sex                                         0.80 (0.74--0.87)                \<0.001               0.74 (0.68--0.80)             \<0.001   0.76 (0.71--0.82)   \<0.001
  Age (by 10 y)                                    1.48 (1.41--1.56)                \<0.001               1.54 (1.45--1.64)             \<0.001   1.35 (1.29--1.42)   \<0.001
  Duration of diabetes mellitus (by 10 y)          1.00 (0.95--1.05)                0.936                 0.97 (0.92--1.02)             0.235     1.00 (0.95--1.04)   0.953
  BMI (by 5 kg/m^2^)                               1.09 (1.05--1.14)                \<0.001               1.08 (1.04--1.13)             \<0.001   1.07 (1.04--1.11)   \<0.001
  eGFR (by 10 mL/min per 1.73 m^2^)                0.40 (0.38--0.41)                \<0.001               1.07 (1.03--1.11)             \<0.001   0.53 (0.51--0.54)   \<0.001
  Microalbuminuria                                 1.69 (1.53--1.86)                \<0.001               1.77 (1.59--1.96)             \<0.001   1.70 (1.55--1.86)   \<0.001
  Macroalbuminuria                                 4.49 (3.65--5.52)                \<0.001               4.23 (3.45--5.19)             \<0.001   4.05 (3.34--4.92)   \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         1.06 (0.97--1.15)                0.172                 1.04 (0.95--1.14)             0.358     1.05 (0.97--1.13)   0.234
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          1.17 (1.07--1.27)                \<0.001               1.18 (1.08--1.30)             \<0.001   1.18 (1.09--1.27)   \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   1.09 (1.00--1.19)                0.039                 1.12 (1.02--1.23)             0.017     1.09 (1.01--1.18)   0.024
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    0.84 (0.78--0.91)                \<0.001               0.80 (0.73--0.87)             \<0.001   0.84 (0.79--0.9)    \<0.001
  Nonproliferative retinopathy                     1.11 (1.00--1.24)                0.054                 1.12 (0.99--1.26)             0.061     1.11 (1.00--1.22)   0.051
  Proliferative retinopathy                        1.27 (1.06--1.53)                0.009                 1.20 (0.99--1.46)             0.062     1.28 (1.08--1.51)   0.004
  Lipid‐lowering treatment                         0.93 (0.86--1.01)                0.090                 0.92 (0.84--1.01)             0.071     0.93 (0.86--1.00)   0.041
  Antihypertensive treatment                       1.42 (1.23--1.64)                \<0.001               1.35 (1.15--1.58)             \<0.001   1.37 (1.20--1.56)   \<0.001
  Treatment with ACE‐Is/ARBs                       0.95 (0.84--1.06)                0.347                 0.92 (0.81--1.05)             0.205     0.96 (0.86--1.06)   0.403
  Aspirin                                          1.08 (0.99--1.18)                0.086                 1.03 (0.93--1.13)             0.616     1.08 (1.00--1.17)   0.059
  Antidiabetic therapy                                                                                                                                                
  Diet                                             0.72 (0.61--0.86)                \<0.001               0.69 (0.56--0.85)             \<0.001   0.73 (0.62--0.85)   \<0.001
  Oral antidiabetic drugs                          1.00                                                   1.00                                    1.00                
  Oral antidiabetic drugs and insulin              1.24 (1.11--1.38)                \<0.001               1.24 (1.11--1.40)             \<0.001   1.23 (1.12--1.37)   \<0.001
  Insulin                                          1.24 (1.09--1.40)                0.001                 1.20 (1.04--1.38)             0.010     1.23 (1.09--1.38)   0.001
  Group ATRH and BPC                                                                                                                                                  
  No ATRH and BPC                                  1.00                                                   1.00                                    1.00                
  No ATRH and No BPC                               1.05 (0.94--1.18)                0.393                 1.00 (0.87--1.13)             0.940     1.04 (0.93--1.16)   0.486
  ATRH and BPC                                     1.78 (1.37--2.32)                \<0.001               1.87 (1.43--2.45)             \<0.001   1.68 (1.32--2.15)   \<0.001
  ATRH and No BPC                                  1.32 (1.15--1.52)                \<0.001               1.37 (1.18--1.59)             \<0.001   1.30 (1.14--1.48)   \<0.001

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete‐case analysis including 24 640 patients for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

The relationship between aTRH, BPC, and future development of renal outcome was further investigated on the basis of sex and age. Results (Tables [5](#jah32537-tbl-0005){ref-type="table-wrap"}, [6](#jah32537-tbl-0006){ref-type="table-wrap"}, [7](#jah32537-tbl-0007){ref-type="table-wrap"}, [8](#jah32537-tbl-0008){ref-type="table-wrap"}, [9](#jah32537-tbl-0009){ref-type="table-wrap"} through [10](#jah32537-tbl-0010){ref-type="table-wrap"}) substantially confirm main study findings and emphasize that renal risk is particularly elevated in older patients, and in those with aTRH reaching very low blood pressure values (ie, those with BPC).

###### 

Baseline Characteristics of Study Patients Stratified by Sex

                                                                   Women            Men              *P* Value
  ---------------------------------------------------------------- ---------------- ---------------- -----------
  Age, y                                                           66±9             64±9             \<0.001
  Known duration of diabetes mellitus, y                           11±9             10±8             \<0.001
  BMI, kg/m^2^                                                     30±6             29±4             \<0.001
  Serum creatinine, μmol/L                                         64±11            81±13            \<0.001
  eGFR, mL/min per 1.73 m^2^                                       85±13            86±13            \<0.001
  Albuminuria                                                      1970 (15.2%)     3904 (23.0%)     \<0.001
  Microalbuminuria                                                 1744 (13.5%)     3377 (19.9%)     \<0.001
  Macroalbuminuria                                                 226 (1.7%)       527 (3.1%)       \<0.001
  Serum uric acid, μmol/L                                          297±111          329±90           \<0.001
  SUA in the top sex‐specific quintile                             1189 (18.4%)     1689 (20.0%)     0.015
  HbA1c, %                                                         7.4±1.3          7.2±1.3          \<0.001
  HbA1c, mmol/mol                                                  57±14            55±14            \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                                         7362 (57.3%)     8625 (51.2%)     \<0.001
  Total cholesterol, mmol/L                                        5.01±0.95        4.70±0.95        \<0.001
  Triglycerides, mmol/L                                            1.52±0.95        1.57±1.00        \<0.001
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)                          3720 (30.5%)     5060 (31.8%)     0.031
  HDL, mmol/L                                                      1.42±0.39        1.25±0.35        \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)                   4642 (38.7%)     4015 (25.5%)     \<0.001
  LDL, mmol/L                                                      2.93±0.86        2.77±0.84        \<0.001
  LDL ≥100 mg/dL (≥2.59 mmol/L)                                    7602 (63.4%)     8881 (56.9%)     \<0.001
  Systolic BP, mm Hg                                               144±17           143±17           \<0.001
  Diastolic BP, mm Hg                                              81±9             81±9             \<0.001
  BP ≥140/85 mm Hg                                                 9397 (72.5%)     12 314 (72.6%)   0.498
  Nonproliferative retinopathy                                     1645 (12.7%)     2310 (13.6%)     0.079
  Proliferative retinopathy                                        500 (3.9%)       669 (3.9%)       0.565
  Lipid‐lowering treatment                                         794 (11.6%)      1841 (19.5%)     \<0.001
  Treatment with statins                                           6395 (49.4%)     8184 (48.2%)     0.300
  Treatment with fibrates                                          5979 (46.2%)     7477 (44.1%)     0.008
  No. of antihypertensive drugs                                    246 (1.9%)       410 (2.4%)       0.008
  Antihypertensive treatment                                       10 256 (79.2%)   12 850 (75.7%)   \<0.001
  Treatment with ACE‐Is/ARBs                                       8518 (65.8%)     10 994 (64.8%)   0.083
  Aspirin                                                          3543 (27.4%)     5753 (33.9%)     \<0.001
  Antidiabetic therapy                                                                               
  Diet                                                             838 (6.5%)       1339 (7.9%)      \<0.001
  Oral antidiabetic drugs                                          8477 (65.4%)     11 660 (68.7%)   \<0.001
  Oral antidiabetic drugs and insulin                              2285 (17.6%)     2274 (13.4%)     \<0.001
  Insulin                                                          1354 (10.5%)     1696 (10.0%)     0.123
  Apparent resistant hypertension                                  2452 (18.9%)     2537 (15.0%)     \<0.001
  BP control in at least 75% of visits for GFR \<60                1971 (15.2%)     2741 (16.2%)     0.010
  BP control in at least 75% of visits for GFR red \>30%           1988 (15.3%)     2765 (16.3%)     0.010
  BP control in at least 75% of visits for GFR \<60 or red \>30%   1982 (15.3%)     2741 (16.2%)     0.017
  4‐year outcome                                                                                     
  GFR \<60                                                         2809 (21.7%)     2898 (17.1%)     \<0.001
  GFR reduction \>30% than baseline                                1829 (14.1%)     1722 (10.1%)     \<0.001
  GFR \<60 or reduction \>30% than baseline                        3196 (24.7%)     3226 (19.0%)     \<0.001

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Complete‐case analysis including 29 923 patients for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; SUA, serum uric acid.

###### 

Baseline Characteristics of Study Patients Stratified by Age

                                                                   \<55 Years     56 to 65 Years   \>65 Years       *P* Value
  ---------------------------------------------------------------- -------------- ---------------- ---------------- -----------
  Male sex                                                         3023 (63.3%)   6415 (58.0%)     7531 (53.4%)     \<0.001
  Age, y                                                           50±5           61±3             72±5             ...
  Known duration of diabetes mellitus, y                           7±6            9±8              13±9             \<0.001
  BMI, kg/m^2^                                                     31±6           30±5             29±5             \<0.001
  Serum creatinine, μmol/L                                         73±15          74±15            74±14            \<0.001
  eGFR, mL/min per 1.73 m^2^                                       97±13          88±12            80±11            \<0.001
  Albuminuria                                                      1031 (21.6%)   2083 (18.8%)     2760 (19.6%)     \<0.001
  Microalbuminuria                                                 889 (18.6%)    1819 (16.5%)     2413 (17.1%)     0.001
  Macroalbuminuria                                                 142 (3.0%)     264 (2.4%)       347 (2.5%)       0.139
  Serum uric acid, μmol/L                                          313±85         318±106          314±102          0.073
  SUA in the top sex‐specific quintile                             465 (19.7%)    1062 (19.4%)     1351 (19.1%)     0.809
  HbA1c, %                                                         7.4±1.5        7.3±1.3          7.2±1.2          \<0.001
  HbA1c, mmol/mol                                                  57±17          56±14            55±13            \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                                         2504 (52.8%)   5859 (53.4%)     7624 (54.5%)     0.009
  Total cholesterol, mmol/L                                        4.92±1.01      4.85±0.97        4.78±0.94        \<0.001
  Triglycerides, mmol/L                                            1.78±1.28      1.60±1.05        1.43±0.78        \<0.001
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)                          1751 (39.0%)   3548 (34.1%)     3481 (26.3%)     \<0.001
  HDL, mmol/L                                                      1.24±0.34      1.30±0.36        1.37±0.39        \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)                   1666 (37.3%)   3402 (33.1%)     3589 (27.6%)     \<0.001
  LDL, mmol/L                                                      2.92±0.90      2.85±0.85        2.80±0.83        \<0.001
  LDL ≥100 mg/dL (≥2.59 mmol/L)                                    2773 (63.2%)   6155 (60.3%)     7555 (58.1%)     \<0.001
  Systolic BP, mm Hg                                               139±17         142±17           145±17           \<0.001
  Diastolic BP, mm Hg                                              84±9           82±9             80±9             \<0.001
  BP ≥140/85 mm Hg                                                 3391 (71.1%)   7949 (71.9%)     10 371 (73.6%)   \<0.001
  Nonproliferative retinopathy                                     537 (11.3%)    1424 (12.9%)     1994 (14.1%)     \<0.001
  Proliferative retinopathy                                        154 (3.2%)     428 (3.9%)       587 (4.2%)       0.034
  Lipid‐lowering treatment                                         722 (25.9%)    1158 (18.8%)     755 (10.3%)      \<0.001
  Treatment with statins                                           1973 (41.3%)   5538 (50.1%)     7068 (50.1%)     \<0.001
  Treatment with fibrates                                          1714 (35.9%)   5078 (45.9%)     6664 (47.3%)     \<0.001
  No. of antihypertensive drugs                                    172 (3.6%)     272 (2.5%)       212 (1.5%)       \<0.001
  Antihypertensive treatment                                       3343 (70.1%)   8379 (75.8%)     11 384 (80.7%)   \<0.001
  Treatment with ACE‐Is/ARBs                                       2878 (60.3%)   7154 (64.7%)     9480 (67.2%)     \<0.001
  Aspirin                                                          921 (19.3%)    3299 (29.8%)     5076 (36.0%)     \<0.001
  Antidiabetic therapy                                                                                              
  Diet                                                             403 (8.4%)     862 (7.8%)       912 (6.5%)       \<0.001
  Oral antidiabetic drugs                                          3219 (67.5%)   7503 (67.9%)     9415 (66.8%)     0.077
  Oral antidiabetic drugs and insulin                              678 (14.2%)    1734 (15.7%)     2147 (15.2%)     0.018
  Insulin                                                          472 (9.9%)     953 (8.6%)       1625 (11.5%)     \<0.001
  Apparent resistant hypertension                                  512 (10.7%)    1761 (15.9%)     2716 (19.3%)     \<0.001
  BP control in at least 75% of visits for GFR \<60                989 (20.7%)    1788 (16.2%)     1935 (13.7%)     \<0.001
  BP control in at least 75% of visits for GFR red \>30%           992 (20.8%)    1803 (16.3%)     1958 (13.9%)     \<0.001
  BP control in at least 75% of visits for GFR \<60 or red \>30%   988 (20.7%)    1796 (16.3%)     1939 (13.8%)     \<0.001
  4‐year outcome                                                                                                    
  GFR \<60 mL/min per 1.73 m^2^                                    274 (5.7%)     1519 (13.7%)     3914 (27.8%)     \<0.001
  GFR reduction \>30% than baseline                                362 (7.6%)     1122 (10.2%)     2067 (14.7%)     \<0.001
  GFR \<60 or reduction \>30% than baseline                        458 (9.6%)     1836 (16.6%)     4128 (29.3%)     \<0.001

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Complete‐case analysis including 29 923 patients for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; SUA, serum uric acid.

###### 

Multivariate Analysis by Sex for the Occurrence of 4‐Year Renal Outcome eGFR \<60 mL/min per 1.73 m^2^

                                                   Women               Men                           
  ------------------------------------------------ ------------------- --------- ------------------- ---------
  Age (by 10 y)                                    1.51 (1.39--1.63)   \<0.001   1.48 (1.37--1.59)   \<0.001
  Duration of diabetes mellitus (by 10 y)          0.97 (0.90--1.04)   0.375     1.02 (0.95--1.09)   0.616
  BMI (by 5 kg/m^2^)                               1.09 (1.04--1.15)   0.001     1.09 (1.02--1.16)   0.008
  eGFR (by 10 mL/min per 1.73 m^2^)                0.42 (0.40--0.44)   \<0.001   0.38 (0.36--0.40)   \<0.001
  Microalbuminuria                                 1.51 (1.29--1.78)   \<0.001   1.78 (1.57--2.03)   \<0.001
  Macroalbuminuria                                 4.00 (2.76--5.80)   \<0.001   4.55 (3.54--5.86)   \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         1.08 (0.96--1.22)   0.218     1.05 (0.94--1.17)   0.419
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          1.09 (0.96--1.23)   0.192     1.26 (1.12--1.41)   \<0.001
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   1.06 (0.94--1.19)   0.350     1.13 (1.00--1.28)   0.043
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    0.80 (0.71--0.89)   \<0.001   0.87 (0.78--0.97)   0.009
  Nonproliferative retinopathy                     1.13 (0.96--1.33)   0.131     1.07 (0.93--1.25)   0.350
  Proliferative retinopathy                        1.33 (1.02--1.73)   0.037     1.25 (0.98--1.61)   0.074
  Lipid‐lowering treatment                         0.92 (0.82--1.03)   0.132     0.94 (0.84--1.06)   0.315
  Antihypertensive treatment                       1.49 (1.21--1.83)   \<0.001   1.36 (1.11--1.66)   0.003
  Treatment with ACE‐Is/ARBs                       0.93 (0.79--1.09)   0.374     0.95 (0.81--1.12)   0.565
  Aspirin                                          1.19 (1.05--1.35)   0.007     1.00 (0.88--1.12)   0.946
  Antidiabetic therapy                                                                               
  Diet                                             0.76 (0.59--0.97)   0.029     0.69 (0.54--0.87)   0.002
  Oral antidiabetic drugs                          1.00                          1.00                
  Oral antidiabetic drugs and insulin              1.26 (1.08--1.47)   0.003     1.25 (1.07--1.46)   0.006
  Insulin                                          1.16 (0.97--1.40)   0.109     1.34 (1.13--1.59)   0.001
  Group ATRH and BPC                                                                                 
  No ATRH and BPC                                  1.00                          1.00                
  No ATRH and No BPC                               1.01 (0.85--1.19)   0.952     1.09 (0.93--1.28)   0.294
  ATRH and BPC                                     1.56 (1.07--2.28)   0.022     2.01 (1.39--2.91)   \<0.001
  ATRH and No BPC                                  1.18 (0.96--1.44)   0.110     1.47 (1.21--1.78)   \<0.001

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete‐case analysis including 10 614 women and 14 026 men for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

###### 

Multivariate Analysis by Sex for the Occurrence of 4‐Year Renal Outcome eGFR Reduction ≥30%

                                                   Women               Men                           
  ------------------------------------------------ ------------------- --------- ------------------- ---------
  Age (by 10 y)                                    1.53 (1.41--1.66)   \<0.001   1.58 (1.45--1.72)   \<0.001
  Duration of diabetes mellitus (by 10 y)          0.99 (0.91--1.07)   0.741     0.95 (0.88--1.02)   0.173
  BMI (by 5 kg/m^2^)                               1.07 (1.01--1.13)   0.017     1.10 (1.03--1.18)   0.006
  eGFR (by 10 mL/min per 1.73 m^2^)                1.10 (1.04--1.16)   \<0.001   1.06 (1.00--1.12)   0.036
  Microalbuminuria                                 1.53 (1.30--1.81)   \<0.001   1.92 (1.68--2.21)   \<0.001
  Macroalbuminuria                                 3.99 (2.77--5.73)   \<0.001   4.21 (3.29--5.39)   \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         1.01 (0.88--1.15)   0.926     1.08 (0.95--1.23)   0.213
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          1.15 (1.01--1.32)   0.034     1.23 (1.08--1.39)   0.002
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   1.09 (0.96--1.23)   0.188     1.17 (1.02--1.34)   0.023
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    0.77 (0.68--0.87)   \<0.001   0.82 (0.73--0.92)   0.001
  Nonproliferative retinopathy                     1.11 (0.93--1.32)   0.236     1.12 (0.95--1.32)   0.185
  Proliferative retinopathy                        1.24 (0.94--1.64)   0.130     1.19 (0.91--1.56)   0.212
  Lipid‐lowering treatment                         0.88 (0.78--1.00)   0.054     0.97 (0.85--1.10)   0.589
  Antihypertensive treatment                       1.41 (1.13--1.76)   0.002     1.27 (1.01--1.59)   0.040
  Treatment with ACE‐Is/ARBs                       0.91 (0.76--1.08)   0.258     0.94 (0.78--1.13)   0.511
  Aspirin                                          1.07 (0.93--1.23)   0.324     0.97 (0.85--1.11)   0.682
  Antidiabetic therapy                                                                               
  Diet                                             0.61 (0.44--0.84)   0.002     0.74 (0.56--0.97)   0.032
  Oral antidiabetic drugs                          1.00                          1.00                
  Oral antidiabetic drugs and insulin              1.23 (1.04--1.44)   0.014     1.29 (1.09--1.53)   0.003
  Insulin                                          1.31 (1.08--1.59)   0.006     1.11 (0.91--1.35)   0.310
  Group ATRH and BPC                                                                                 
  No ATRH and BPC                                  1.00                          1.00                
  No ATRH and No BPC                               0.86 (0.72--1.04)   0.113     1.15 (0.95--1.39)   0.149
  ATRH and BPC                                     1.66 (1.14--2.43)   0.008     2.12 (1.44--3.13)   \<0.001
  ATRH and No BPC                                  1.18 (0.96--1.46)   0.123     1.61 (1.29--2.00)   \<0.001

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete‐case analysis including 10 614 women and 14 026 men for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

###### 

Multivariate Analysis by Groups of Age for the Occurrence of 4‐Year Renal Outcome eGFR \<60 mL/min per 1.73 m^2^

                                                   Age ≤55 Years       Age 56 to 65 Years   Age \>65 Years                                    
  ------------------------------------------------ ------------------- -------------------- ------------------- --------- ------------------- ---------
  Male sex                                         0.85 (0.62--1.16)   0.296                0.79 (0.68--0.90)   0.001     0.80 (0.73--0.89)   \<0.001
  Age (by 10 y)                                    1.01 (0.72--1.41)   0.954                1.60 (1.25--2.05)   \<0.001   1.52 (1.37--1.69)   \<0.001
  Duration of diabetes mellitus (by 10 y)          0.94 (0.74--1.21)   0.635                0.92 (0.84--1.02)   0.113     1.03 (0.97--1.09)   0.400
  BMI (by 5 kg/m^2^)                               1.11 (0.97--1.26)   0.124                1.03 (0.96--1.10)   0.364     1.13 (1.07--1.19)   \<0.001
  eGFR (by 10 mL/min per 1.73 m^2^)                0.53 (0.47--0.59)   \<0.001              0.43 (0.4--0.45)    \<0.001   0.36 (0.34--0.38)   \<0.001
  Microalbuminuria                                 1.21 (0.83--1.75)   0.324                1.70 (1.42--2.03)   \<0.001   1.72 (1.51--1.96)   \<0.001
  Macroalbuminuria                                 4.72 (2.68--8.30)   \<0.001              5.50 (3.94--7.69)   \<0.001   3.47 (2.60--4.65)   \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         1.05 (0.75--1.45)   0.789                1.03 (0.88--1.19)   0.736     1.08 (0.97--1.21)   0.137
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          1.24 (0.91--1.70)   0.176                1.24 (1.07--1.43)   0.004     1.15 (1.03--1.28)   0.014
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   1.07 (0.78--1.46)   0.692                1.02 (0.88--1.19)   0.776     1.12 (1.00--1.25)   0.048
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    0.74 (0.54--1.00)   0.048                0.78 (0.68--0.89)   \<0.001   0.86 (0.78--0.95)   0.003
  Nonproliferative retinopathy                     1.05 (0.67--1.66)   0.827                1.10 (0.90--1.35)   0.337     1.13 (0.98--1.29)   0.084
  Proliferative retinopathy                        1.46 (0.75--2.85)   0.270                1.79 (1.32--2.44)   \<0.001   1.02 (0.81--1.30)   0.850
  Lipid‐lowering treatment                         0.84 (0.62--1.16)   0.295                0.99 (0.85--1.14)   0.840     0.92 (0.83--1.02)   0.096
  Antihypertensive treatment                       2.01 (1.19--3.39)   0.009                1.50 (1.14--1.96)   0.003     1.32 (1.10--1.59)   0.003
  Treatment with ACE‐Is/ARBs                       0.60 (0.39--0.93)   0.022                0.99 (0.79--1.23)   0.903     0.98 (0.85--1.12)   0.740
  Aspirin                                          0.97 (0.66--1.42)   0.871                0.89 (0.76--1.05)   0.168     1.16 (1.04--1.29)   0.008
  Antidiabetic therapy                                                                                                                        
  Diet                                             0.79 (0.42--1.49)   0.466                0.65 (0.47--0.89)   0.007     0.73 (0.59--0.91)   0.005
  Oral antidiabetic drugs                          1.00                                     1.00                          1.00                
  Oral antidiabetic drugs and insulin              1.59 (1.05--2.43)   0.030                1.41 (1.16--1.71)   0.001     1.15 (1.00--1.33)   0.051
  Insulin                                          1.71 (1.06--2.74)   0.027                1.86 (1.48--2.34)   \<0.001   1.03 (0.88--1.21)   0.718
  Group ATRH and BPC                                                                                                                          
  No ATRH and BPC                                  1.00                                     1.00                          1.00                
  No ATRH and No BPC                               0.82 (0.56--1.20)   0.304                1.09 (0.89--1.33)   0.407     1.05 (0.90--1.23)   0.519
  ATRH and BPC                                     1.83 (0.74--4.49)   0.190                1.51 (0.96--2.39)   0.077     1.96 (1.38--2.78)   \<0.001
  ATRH and No BPC                                  1.60 (0.98--2.64)   0.063                1.55 (1.22--1.98)   \<0.001   1.20 (1.00--1.43)   0.050

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete‐case analysis including 3942 patients aged ≤55 years, 9133 aged 56 to 65 years, and 11 565 aged \>65 years for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

###### 

Multivariate Analysis by Groups of Age for the Occurrence of 4‐Year Renal Outcome eGFR Reduction ≥30%

                                                   Age ≤55 Years       Age 56 to 65 Years   Age \>65 Years                                    
  ------------------------------------------------ ------------------- -------------------- ------------------- --------- ------------------- ---------
  Male sex                                         0.75 (0.58--0.99)   0.039                0.69 (0.59--0.80)   \<0.001   0.75 (0.67--0.84)   \<0.001
  Age (by 10 y)                                    1.42 (1.07--1.90)   0.016                1.37 (1.05--1.78)   0.019     1.59 (1.41--1.81)   \<0.001
  Duration of diabetes mellitus (by 10 y)          0.95 (0.76--1.19)   0.657                0.92 (0.83--1.02)   0.124     0.99 (0.92--1.05)   0.659
  BMI (by 5 kg/m^2^)                               1.02 (0.91--1.14)   0.736                1.04 (0.97--1.12)   0.230     1.12 (1.06--1.19)   \<0.001
  eGFR (by 10 mL/min per 1.73 m^2^)                1.26 (1.13--1.40)   \<0.001              1.09 (1.02--1.16)   0.007     1.03 (0.98--1.09)   0.216
  Microalbuminuria                                 1.51 (1.11--2.06)   0.009                1.72 (1.43--2.07)   \<0.001   1.80 (1.56--2.07)   \<0.001
  Macroalbuminuria                                 4.24 (2.48--7.26)   \<0.001              4.80 (3.45--6.68)   \<0.001   3.48 (2.59--4.67)   \<0.001
  HbA1c ≥7% (≥53 mmol/mol)                         1.11 (0.83--1.47)   0.490                1.10 (0.94--1.29)   0.250     1.01 (0.90--1.14)   0.833
  Triglycerides ≥150 mg/dL (≥1.69 mmol/L)          1.28 (0.97--1.68)   0.075                1.26 (1.08--1.47)   0.003     1.13 (1.00--1.28)   0.058
  HDL \<40M \<50F mg/dL (\<1.03M \<1.29F mmol/L)   1.21 (0.92--1.58)   0.168                1.06 (0.91--1.25)   0.442     1.11 (0.98--1.26)   0.093
  LDL ≥100 mg/dL (≥2.59 mmol/L)                    1.03 (0.79--1.34)   0.818                0.72 (0.62--0.84)   \<0.001   0.79 (0.71--0.88)   \<0.001
  Nonproliferative retinopathy                     1.21 (0.82--1.78)   0.336                1.11 (0.90--1.37)   0.340     1.11 (0.95--1.30)   0.176
  Proliferative retinopathy                        1.91 (1.08--3.37)   0.026                1.47 (1.07--2.03)   0.019     0.97 (0.74--1.27)   0.829
  Lipid‐lowering treatment                         0.98 (0.74--1.29)   0.881                1.00 (0.86--1.17)   0.955     0.88 (0.78--0.98)   0.026
  Antihypertensive treatment                       1.57 (0.99--2.48)   0.056                1.29 (0.97--1.71)   0.079     1.30 (1.05--1.60)   0.015
  Treatment with ACE‐Is/ARBs                       0.68 (0.46--1.02)   0.062                0.99 (0.78--1.26)   0.948     0.96 (0.81--1.12)   0.584
  Aspirin                                          0.95 (0.68--1.33)   0.764                0.98 (0.83--1.16)   0.812     1.05 (0.93--1.19)   0.448
  Antidiabetic therapy                                                                                                                        
  Diet                                             0.79 (0.44--1.41)   0.421                0.79 (0.56--1.12)   0.188     0.58 (0.43--0.78)   \<0.001
  Oral antidiabetic drugs                          1.00                                     1.00                          1.00                
  Oral antidiabetic drugs and insulin              1.48 (1.04--2.12)   0.030                1.23 (1.00--1.51)   0.048     1.22 (1.05--1.43)   0.011
  Insulin                                          1.16 (0.73--1.82)   0.532                1.89 (1.49--2.39)   \<0.001   0.94 (0.78--1.13)   0.497
  Group ATRH and BPC                                                                                                                          
  No ATRH and BPC                                  1.00                                     1.00                          1.00                
  No ATRH and No BPC                               0.86 (0.61--1.22)   0.408                1.03 (0.83--1.29)   0.794     1.00 (0.83--1.20)   0.995
  ATRH and BPC                                     1.89 (0.79--4.55)   0.155                1.29 (0.78--2.16)   0.322     2.31 (1.63--3.29)   \<0.001
  ATRH and No BPC                                  1.82 (1.17--2.85)   0.008                1.54 (1.19--2.00)   0.001     1.24 (1.01--1.52)   0.044

Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. For each renal outcome, visits after the event occurrence were excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete‐case analysis including 3942 patients aged ≤55 years, 9133 aged 56 to 65 years, and 11 565 aged \>65 years for which all data were observed. ACE‐Is indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol.

Patients with aTRH showed an increased risk of developing low eGFR and eGFR reduction ≥30% from baseline as compared with those without aTRH. Furthermore, no association was found between BPC and renal outcome in non‐aTRH, whereas in aTRH, BPC was associated with a 30% (*P*=0.036) greater risk to develop either 1 of the renal end points (Table [11](#jah32537-tbl-0011){ref-type="table-wrap"}).

###### 

Comparative Risk for Outcomes Among Different Hypertension Categories

  -------------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------------
  eGFR \<60 mL/min per 1.73 m^2^                                                                                                
  No ATRH and BPC                  Reference                      0.95 (0.85--1.07) *P*=0.393    0.56 (0.43--0.73) *P*\<0.001   0.76 (0.66--0.87) *P*\<0.001
  No ATRH and No BPC               1.05 (0.94--1.18) *P*=0.393    Reference                      0.59 (0.46--0.76) *P*\<0.001   0.80 (0.72--0.88) *P*\<0.001
  ATRH and BPC                     1.78 (1.37--2.32) *P*\<0.001   1.69 (1.32--2.18) *P*\<0.001   Reference                      1.35 (1.04--1.75) *P*=0.024
  ATRH and No BPC                  1.32 (1.15--1.52) *P*\<0.001   1.26 (1.13--1.39) *P*\<0.001   0.74 (0.57--0.96) *P*=0.024    Reference
  eGFR reduction ≥30%                                                                                                           
  No ATRH and BPC                  Reference                      1.01 (0.88--1.14) *P*=0.940    0.54 (0.41--0.70) *P*\<0.001   0.73 (0.63--0.85) *P*\<0.001
  No ATRH and No BPC               1.00 (0.87--1.13) *P*=0.940    Reference                      0.53 (0.41--0.69) *P*\<0.001   0.73 (0.65--0.81) *P*\<0.001
  ATRH and BPC                     1.87 (1.43--2.45) *P*\<0.001   1.88 (1.46--2.42) *P*\<0.001   Reference                      1.36 (1.05--1.77) *P*=0.020
  ATRH and No BPC                  1.37 (1.18--1.59) *P*\<0.001   1.38 (1.23--1.54) *P*\<0.001   0.73 (0.56--0.95) *P*=0.020    Reference
  eGFR \<60 or reduction ≥30%                                                                                                   
  No ATRH and BPC                  Reference                      0.96 (0.87--1.07) *P*=0.486    0.59 (0.47--0.76) *P*\<0.001   0.77 (0.68--0.87) *P*\<0.001
  No ATRH and No BPC               1.04 (0.93--1.16) *P*=0.486    Reference                      0.62 (0.49--0.78) *P*\<0.001   0.80 (0.73--0.88) *P*\<0.001
  ATRH and BPC                     1.68 (1.32--2.15) *P*\<0.001   1.62 (1.28--2.05) *P*\<0.001   Reference                      1.29 (1.02--1.65) *P*=0.036
  ATRH and No BPC                  1.30 (1.14--1.48) *P*\<0.001   1.25 (1.14--1.38) *P*\<0.001   0.77 (0.61--0.98) *P*=0.036    Reference
  -------------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------------

Multivariate odds ratios with 95% confidence interval for each renal outcome according to models listed in Table [4](#jah32537-tbl-0004){ref-type="table-wrap"}. ATRH indicates apparent treatment resistant hypertension; BPC, blood pressure control refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg; eGFR, estimated glomerular filtration rate.

We investigated changes in eGFR along the 4 years of follow‐up on the basis of aTRH and BPC. Associations between changes in eGFR and the presence of aTRH and/or BPC were examined using adjusted mean values of eGFR slope. The yearly mean eGFR slope was significantly higher for the aTRH patients as compared with those with no aTRH independently of BPC. Thus, whereas BPC seems to confer renal protection in patients without aTRH, those with aTRH with and without BPC showed a very similar yearly mean eGFR slope (Figure [4](#jah32537-fig-0004){ref-type="fig"}).

![Mean yearly eGFR slope on the basis of the presence of aTRH and BPC. ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; BP, blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure \<140/90 mm Hg. \**P*\<0.01 vs No‐aTRH with BPC; ^*\#*^ *P*\<0.01 vs No‐aTRH with NoBPC.](JAH3-6-e006745-g004){#jah32537-fig-0004}

The presence of Alb was associated with worse renal prognosis both in patients without aTRH (OR, 2.00; CI, 1.80--2.23; *P*\<0.001) and in those with aTRH (OR, 1.67; CI, 1.38--2.02; *P*\<0.001; Figure [5](#jah32537-fig-0005){ref-type="fig"}A). Furthermore, in the absence of optimal BPC, the presence of Alb entailed greater incidence of low eGFR (Alb+/BPC− versus Alb−/BPC−; OR, 1.98; CI, 1.79--2.19; *P*\<0.001), the unfavorable prognostic role of increased Alb at baseline was unchanged when BPC was obtained (Alb+/BPC+ versus Alb−/BPC+; OR, 1.71; CI, 1.34--2.18; *P*\<0.001; Alb+/BPC+ versus ALB/BPC−; OR, 0.90; CI, 0.72--1.14; *P*=0.379; Figure [5](#jah32537-fig-0005){ref-type="fig"}B).

![A, Cumulative incidence of renal end point (eGFR \<60) on the basis of albuminuria status and aTRH. ALB indicates albuminuria; ATRH, apparent treatment resistant hypertension; CI, confidence interval; eGFR, estimated glomerular filtration rate. \*Adjusted odds ratios for Alb+/aTRH− vs Alb−/aTRH− 2.00 (CI 1.80--2.23), *P*\<0.001 and ^\#^for Alb+/aTRH+ vs Alb−/aTRH+ 1.67 (CI 1.38--2.02), *P*\<0.001. B, Cumulative incidence of renal end point (eGFR \<60) on the basis of albuminuria status and time‐updated BPC. ALB indicates albuminuria; BPC, blood pressure control; eGFR, estimated glomerular filtration rate. \*Adjusted odds ratios for Alb+/BPC− vs Alb−/BPC− 1.98 (CI 1.79--2.19), *P*\<0.001 and ^\#^for Alb+/BPC+ vs Alb−/BPC+ 1.71 (CI 1.34--2.18), *P*\<0.001.](JAH3-6-e006745-g005){#jah32537-fig-0005}

When our data were evaluated on the basis of time‐updated mean SBP, it emerged that aTRH patients showed a greater risk of developing low eGFR as compared with non‐aTRH patients over the entire range of BP (Figure [6](#jah32537-fig-0006){ref-type="fig"}). Furthermore, whereas renal risk decreases along with BP reduction and reaches a nadir between 140 and 120 mm Hg, the achievement of lower SBP values entails a paradoxical increase in the incidence of GFR reduction, thereby confirming the existence of a J‐curve relationship between SBP and renal function.

![Odds ratios of reaching renal end point (eGFR \<60 mL/min per 1.73 m^2^) on the basis of time‐updated mean SBP in patients with and without aTRH, taking 140 mm Hg in non aTRH as reference category. Patients were grouped into 10 mm Hg subsets (ie, those between 136 and 144 in the group labeled 140 and so on). The subset of patients with No‐aTRH and 140 mm Hg SBP was taken as the reference group. ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure. Odds ratio for single renal outcome with 95% confidence interval.](JAH3-6-e006745-g006){#jah32537-fig-0006}

Discussion {#jah32537-sec-0015}
==========

Our study shows that, in a real‐life clinical setting, in hypertensive T2D patients with normal renal function, the presence of aTRH entails a greater risk of developing CKD or a significant worsening of eGFR over a 4‐year follow‐up period. Furthermore, the achievement and maintenance of optimal BPC does not seem to be associated with renal protection over time.

Although several studies conducted on high‐risk hypertensive patients have previously shown that aTRH entails a greater cardiovascular and mortality risk,[6](#jah32537-bib-0006){ref-type="ref"}, [10](#jah32537-bib-0010){ref-type="ref"}, [13](#jah32537-bib-0013){ref-type="ref"} to date only 2 studies have investigated long‐term renal outcome, namely the development of ESRD.[12](#jah32537-bib-0012){ref-type="ref"}, [22](#jah32537-bib-0022){ref-type="ref"}

In a secondary analysis of the ALLHAT (Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial) study, aTRH was associated with a 2‐fold greater risk of ESRD, especially in the presence of diabetes mellitus even after adjustment for confounders such as baseline GFR values.[22](#jah32537-bib-0022){ref-type="ref"} Similarly, Sim et al[12](#jah32537-bib-0012){ref-type="ref"} in a retrospective analysis of the large Kaiser Permanente cohort of general hypertensive patients from southern California, reported a 30% greater risk of ESRD over a 5‐year follow‐up period in the subgroup of patients with RH.

Both these studies, however, included a relevant proportion of patients with CKD at baseline. In fact, in the Kaiser Permanente cohort, up to 30% of patients had CKD at baseline and eGFR was, on average, 60 mL/min in the aTRH subgroup. Furthermore, results from the ALLHAT study have been questioned because of the specific intervention protocol and definition of RH.

In a further, retrospective, cohort study conducted on subjects with incident hypertension in a US Registry, those who went on to develop RH, after multivariate adjustment, were at higher risk for cardiovascular outcomes and for the development of stage 3 CKD as compared with those with non‐RH over a 4‐year follow‐up.[11](#jah32537-bib-0011){ref-type="ref"}

Our study is the first, to our knowledge, to investigate the impact of aTRH on the early stages of kidney damage in a high‐renal‐risk population of patients such as those with T2D and hypertension. The choice of intermediate, but well‐established, end points such as the development of stage 3 CKD and a 30% reduction in eGFR, which have been shown to predict and precede progression to ESRD,[23](#jah32537-bib-0023){ref-type="ref"}, [24](#jah32537-bib-0024){ref-type="ref"} allowed us to accurately investigate the onset of renal function impairment over the 4 years of study follow‐up.

The prevalence and clinical characteristics of patients with aTRH we observed in the present study are comparable to what has been previously reported in similar high‐risk groups.[25](#jah32537-bib-0025){ref-type="ref"} Over the follow‐up period, in our generally well‐treated cohort, 19% of patients developed stage 3 CKD (ie, a eGFR value below 60 mL/min) and 12% showed a significant eGFR reduction (ie, ≥30%) from baseline. In patients with aTRH, the presence of a worse cardiovascular risk profile, namely older age, body mass index, a reduction in eGFR, a worse lipid profile, or the presence of Alb or proliferative retinopathy were independent predictors of worse renal outcome. Furthermore, the presence of aTRH entailed a faster decline in renal function over time, despite the achievement of recommended BP values (Figure [4](#jah32537-fig-0004){ref-type="fig"}). As expected, the presence of Alb was associated with a greater risk of renal function loss in both aTRH and non‐aTRH patients (Figure [5](#jah32537-fig-0005){ref-type="fig"}A).

It has been proposed that the RH population has an adverse physiology and is therefore at greater risk for morbidity and mortality. Thus, pathogenetic mechanisms as well as clinical characteristics underlying the development of cardiovascular and renal events, including BP changes and therapeutic strategies, deserve better understanding given that this may lead to optimization of therapeutic strategies for BP reduction and comorbidities.[7](#jah32537-bib-0007){ref-type="ref"}

We sought to further categorize aTRH resistant hypertension on the basis of BPC. By looking at time‐updated BPC, we were able to assess the impact of BP reduction and of the persistence of good BP values over time before each renal end point was reached, if any (Table [11](#jah32537-tbl-0011){ref-type="table-wrap"}). Moreover, we found that the cumulative incidence of stage 3 CKD in patients with low mean time‐updated SBP (ie, \<130 mm Hg) was greater than that observed in patients who achieved less‐tight BP reduction independently of aTRH (Figure [6](#jah32537-fig-0006){ref-type="fig"}).

The subgroup of patients with tightly controlled hypertension not only had lower BP, but were also more likely to have a statin prescription and to have lower values of low‐density lipoprotein cholesterol, a finding that makes low adherence to prescribed medications an unlikely explanation for worse renal outcomes.

Our results are in keeping with those reported by Egan et al,[15](#jah32537-bib-0015){ref-type="ref"} who also found that tight control, as compared with usual, is associated with worse cardiovascular outcomes both in patients with and without aTRH. Along the same line, more recently, in a pooled retrospective analysis of the Ontarget/Transcend database,[26](#jah32537-bib-0026){ref-type="ref"} lowering BP to less than 130 mm Hg SBP was found to be associated with increased rates for cardiovascular events and mortality in patients at high cardiovascular risk.

The relationship between BPC and renal outcome in aTRH has been, so far, investigated only in the analysis by Sim et al, who observed a 25% greater risk for ESRD in individuals with uncontrolled RH as compared with controlled RH,[12](#jah32537-bib-0012){ref-type="ref"} a finding that seems to differ from those reported here.

In the Kaiser Permanente study, however, only baseline BP values were analyzed to assess the degree of BP control, therefore assuming that once individuals are categorized at baseline, they remain so thorough the observation period; in contrast, our use of a dynamic indicator of BPC allowed us a more‐powerful representation of a real‐world clinical scenario. In fact, a significant proportion of patients (up to 20% in our database over the study period) could have been misclassified if analyzed only at baseline, given that both treatment and degree of BPC could change over time.

In the presence of Alb, a well‐known independent predictor of unfavorable cardiovascular and renal prognosis in patients with T2D and hypertension, a more‐ambitious target BP than the traditional 140/90 mm Hg has been proposed by some guidelines to convey greater renal protection.[1](#jah32537-bib-0001){ref-type="ref"}, [6](#jah32537-bib-0006){ref-type="ref"} In our study, patients with Alb and BPC (ie, \<140/90) showed similar renal prognosis as compared with those with less‐tight BPC (Figure [5](#jah32537-fig-0005){ref-type="fig"}B). We performed further analyses to assess whether, in the presence of micro‐ or macro‐Alb, achievement of very low BP values (ie, \<130/80 mm Hg) were associated with better renal outcome. We found that patients with Alb with BP values below 130/80 in at least 75% of study visits showed a 31% incidence of stage 3 CKD as compared with 26% in those with less‐tight BP, again suggesting the presence of a J‐curve phenomenon, which may limit renal protection.

Thus, the presence of aTRH entails a greater renal risk in hypertensive patients with T2D as compared with non‐aTRH patients. The achievement and maintenance of recommended BP values is associated with a worse renal prognosis even more so when time‐updated SBP is lowered below 120 mm Hg, a condition that is associated with increased renal function loss even in non‐aTRH patients.

Although the observational nature of our study does not allow us to infer causality from reported associations, the worse renal prognosis observed in patients with aTRH and BPC supports the existence of a J‐curve phenomenon linking BP reduction and renal function.

Furthermore, we cannot rule out an unfavorable renal effect of renin‐angiotensin‐aldosterone system I in frail, high‐risk patients as those with aTRH, where BP reduction was obtained using a greater *load* of antihypertensive drugs (Table [3](#jah32537-tbl-0003){ref-type="table-wrap"}), in particular renin‐angiotensin‐aldosterone system I. In fact, it has recently been proposed that even mild GFR reduction after initiation of treatment with angiotensin‐converting enzyme inhibitors or angiotensin II receptor antagonists might entail a worse renal prognosis in the long run,[27](#jah32537-bib-0027){ref-type="ref"} at least in a specific subgroup of patients, an issue that is currently being investigated by specifically designed ongoing studies.[28](#jah32537-bib-0028){ref-type="ref"}

Our study has some limitations as well as several strengths that should be mentioned. Among the first ones, we must acknowledge that laboratory parameters, including serum creatinine, were not measured in a single, centralized laboratory and this may have led to some variability in GFR estimation. We did not gather information on specific dosage of antihypertensive medications prescribed to each patient to confirm diagnosis of aTRH. However, BP control significantly improved, on average, over the 4‐year study period, suggesting an attempt toward a therapeutic strategy of up‐titration to maximum tolerated dose. Furthermore, our data may not be applicable to the population with T2D and hypertension at large because the vast majority of participants were of white origin, and ethnicity has previously been shown to bear some impact on the risk of developing renal complications.[29](#jah32537-bib-0029){ref-type="ref"} Finally, we did not have information on extrarenal complications, such as myocardial infarction and stroke, which may affect BP or renal function changes over time. On the other hand, the large size and homogeneous clinical characteristics of the study cohort, as well as the representative geographical distribution of the recruiting centers and the relatively long follow‐up period, do contribute to make our results a reliable representation of real‐life clinical condition. Moreover, at variance with several previous studies on the impact of RH on cardiovascular and renal outcomes,[10](#jah32537-bib-0010){ref-type="ref"}, [11](#jah32537-bib-0011){ref-type="ref"}, [12](#jah32537-bib-0012){ref-type="ref"}, [13](#jah32537-bib-0013){ref-type="ref"}, [14](#jah32537-bib-0014){ref-type="ref"}, [15](#jah32537-bib-0015){ref-type="ref"} we used a very accurate definition of RH, which included the use of diuretics. Another strength of our work is the use of time‐updated BP values as an indicator of achievement and maintenance of BPC over time.

Further studies are clearly needed to investigate the pathophysiological mechanism underlying the effect of BP reduction per se as well as different pharmacological strategies on renal outcome in high‐risk hypertensive patients such as those with diabetes mellitus.

In conclusion, our large, real‐life cohort study shows that in hypertensive patients with T2D, the presence of aTRH entails a significantly greater risk of developing CKD and/or a clinically relevant reduction in eGFR over a 4‐year follow‐up. Interestingly, the achievement and maintenance of optimal BP values are associated with worse renal outcome. The relationship between achieved BP and renal function seems to be J‐shaped, at least at very low levels, with optimal SBP values between 120 and 140 mm Hg.
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**Appendix S1.** AMD ANNALS Study Group.

###### 

Click here for additional data file.

[^1]: A complete list of the AMD‐Annals Study Group members are given in Appendix [S1](#jah32537-sup-0001){ref-type="supplementary-material"}.
